E89: GDP growth negative in Q2, $SHOP layoffs, Alzheimer's fraud, Ginkgo acquires Zymergen & more

The clearest business lesson was that many companies mistook a temporary COVID demand spike for a permanent shift. Shopify cut about 10% of staff after Tobi Lütke admitted that bet was wrong, while Amazon paused buildings and backed away from roughly 15 warehouse projects after overexpanding.

Remote work widened hiring pools but broke old management signals, forcing companies to invent better ways to measure output. Jason Calacanis described writer pods, shared Zoom or Slack sessions, and a “write-first” culture using Notion or Coda change logs so managers could see actual deliverables rather than office presence.

Telehealth looked like one COVID behavior that retained a substantial post-lockdown gain. Friedberg cited 36% of patients using telehealth in 2021—about 420% above 2019—with women around 60% of users, arguing that many consultations never required an in-person visit.

The most consequential discussion concerned how science can lock onto a weak premise when careers, grants, and prestige reward extending it rather than retesting it. The panel centered on alleged image manipulation in a landmark 2006 Alzheimer’s paper and argued that replication offered little career upside even as amyloid research absorbed enormous funding.

They used the serotonin theory of depression as a second warning against confusing an entrenched research narrative with settled evidence. Friedberg cited a large review spanning 17 studies and hundreds of thousands of patients that challenged the low-serotonin explanation, while emphasizing how large commercial markets can reinforce research built around accepted ideas.

Zymergen became the business case for what happens when a compelling scientific story outruns industrial economics. After raising about $1.5 billion and reaching a multibillion-dollar public valuation, it agreed to be acquired for roughly $300 million; Friedberg blamed scale-up problems, facility choices, product strategy, and assumptions that proved weaker in production than in the pitch.

Zymergen’s collapse did not invalidate synthetic biology; it showed that a real technology can still be years ahead of a viable business model. Friedberg contrasted failed industrial-biology ventures with Genentech’s recombinant insulin and a biologics drug industry he put at roughly $350 billion annually, arguing that product choice and timing determine whether science becomes economics.